Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer

AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.

(2015) Leonidas Platanias et al.   Oncotarget

Metformin: Multi-faceted protection against cancer

(2015) Sonia Del Barco et al.   Oncotarget

Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts

(2015) Sílvia Cufí et al.   Oncotarget

Metformin Temporal and Localized Effects on Gut Glucose Metabolism Assessed Using 18F-FDG PET in Mice

(2013) M. Massollo et al.   JOURNAL OF NUCLEAR MEDICINE

Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II

(2013) Barbara Salani et al.   Scientific Reports

Metformin is synthetically lethal with glucose withdrawal in cancer cells

(2012) Javier A. Menendez et al.   CELL CYCLE

Metformin selectively affects human glioblastoma tumor-initiating cell viability

(2012) Roberto Würth et al.   CELL CYCLE

Mitochondrial dysfunction in breast cancer cells prevents tumor growth

(2012) Rosa Sanchez-Alvarez et al.   CELL CYCLE

Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells

(2012) Chang W. Song et al.   Scientific Reports

Understanding the benefit of metformin use in cancer treatment

(2011) Ryan JO Dowling et al.   BMC Medicine

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

(2011) Irina N. Alimova et al.   CELL CYCLE

Metformin abolishes increased tumor18F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet

(2011) Haider Mashhedi et al.   CELL CYCLE

Cellular and molecular mechanisms of metformin: an overview

(2011) Benoit Viollet et al.   CLINICAL SCIENCE

Direct relationship between cell density and FDG uptake in asymptomatic aortic aneurysm close to surgical threshold: an in vivo and in vitro study

(2011) Cecilia Marini et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Subcellular Localization of Hexokinases I and II Directs the Metabolic Fate of Glucose

(2011) Scott John et al.   PLoS One

Metformin: A Therapeutic Opportunity in Breast Cancer

(2010) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Metformin: Taking away the candy for cancer?

(2010) Mathilde Jalving et al.   EUROPEAN JOURNAL OF CANCER

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

(2009) Sao Jiralerspong et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of the Role of Hexokinase Type II in Cellular Proliferation and Apoptosis Using Human Hepatocellular Carcinoma Cell Lines

(2009) K. J. Ahn et al.   JOURNAL OF NUCLEAR MEDICINE

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model

(2008) Kathryn N. Phoenix et al.   BREAST CANCER RESEARCH AND TREATMENT

Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer

(2008) Pamela J. Goodwin et al.   Clinical Breast Cancer

Targeting AMPK: A new therapeutic opportunity in breast cancer

(2008) Sirwan M. Hadad et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Glucose sensing by MondoA:Mlx complexes: A role for hexokinases and direct regulation of thioredoxin-interacting protein expression

(2008) C. A. Stoltzman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapy

(2008) Saroj P. Mathupala et al.   SEMINARS IN CANCER BIOLOGY